- Details
- Joining Alicia Morgans at ASCO GU is Arjun Balar, a bladder cancer expert at New York University, who speaks to the most recent clinical trials and the future direction of available regimens regarding bladder preservation protocols. For the past 30 years, muscle-invasive urothelial cancer patients have been given two options for treatment: radical cystectomy or cisplatinum. With the more recent av...
|
- Details
- Michael O'Donnell shares his insight into managing the current BCG shortage crisis, highlighting ways to make the most out of the current supply and explains a few alternative intravesical agents that could be used in place of BCG for treating patients with bladder cancer. Dr. O'Donnell explains how risk can be assessed while prioritizing high-risk patients and shares advice as to how treatment pl...
|
- Details
- Joshua Meeks joins Alicia Morgans to review his approach to cystoscopy using blue light and Cysview®, and how to best choose patients that will maximally benefit from that kind of technology. Dr. Meeks and Dr. Morgans also review the new approval of pembrolizumab in the BCG unresponsive high-risk non-muscle invasive bladder cancer (NMIBC). Biographies: Josh J. Meeks, MD, Ph.D., Assistant Professor...
|
- Details
- Joshua Meeks joins Alicia Morgans to discuss the current BCG shortage and its implications for treatment options in the bladder cancer community. Dr. Meeks highlights clinical data on the matter presented by other clinicians at the conference, as well as his own personal expertise on how he manages the patient selection and the risk stratification process for BCG resources in his own clinic. Biogr...
|
- Details
- Medical Oncologist and co-leader of the Women's Bladder Cancer Program at John Hopkins, Jean Hoffman-Censits joins Alicia Morgans to speak about bladder cancer in women and the initiatives and importance of the Women's Bladder Cancer Program. In many cases, there are significant delays in diagnosing bladder cancer in women. Dr. Hoffman-Censits discusses the continuous narrative of the delay in dia...
|
- Details
- For this Journal Club, Christopher Wallis, MD, and Zach Klasseen, MD discuss a recently published meta-analysis on treatment options for patients with non-muscle invasive bladder cancer unresponsive or refractory to BCG therapy. They provide context for this review and discuss the clinical relevance of managing the risk of recurrence in NMIBC. Biographies: Zachary Klaassen, MD, MSc, Urologic Oncol...
|
- Details
- In this discussion, Josh Meeks joins Alicia Morgans to review the new advances phase III Nadofaragene Firadenovec (Adstiladrin®) trial for BCG unresponsive non-muscle invasive bladder cancer patients. Dr. Meeks details the results of this recently presented trial data and why he believes this is the beginning of the next era in treating these patients. Biographies: Josh J. Meeks, MD, Ph.D., Assist...
|
- Details
- Sam Chang joins Ashish Kamat to discuss strategies for clinical trials and patient selection required in the face of the world-wide shortage of BCG. Biographies: Sam S. Chang, MD, MBA , Patricia and Rodes Hart Endowed Chair of Urologic Surgery Professor Department of Urology at Vanderbilt University Medical Center, Department of Urology Ashish Kamat, MD, MBBS Professor of Urology and Wayne B. Dudd...
|
- Details
- Joshua Meeks joins Ashish Kamat in discussing the most recent relevant research papers in bladder cancer. Together they explore the publications on checkpoint inhibitors, the use of The Cancer Genome Atlas, Enhanced Recovery after Cystectomy and the impact of blue light flexible cystoscopy with CYSVIEW. Biographies: Josh J. Meeks, MD, Ph.D., Assistant Professor of Urology and Biochemistry and Mole...
|
- Details
- Sima Porten joins Ashish Kamat in a conversation regarding post-operative care of radical cystectomy patients. As someone who has first-hand experience in the difficulty of a culture shift in this process, Dr. Porten outlines how clinics can successfully adopt the ERAS protocol for radical cystectomy, emphasizing the importance of its effectiveness driving a team mentality in the clinical setting....
|
